TABLE 2.
Plasmids used in this study
| Plasmid | Description | Resistancea | Reference or source |
|---|---|---|---|
| pSET152 | ϕC31 int + attP integrating vector | Apra | 64 |
| pEHISTEV | Expression vector, T7 promoter, C-terminal His6, TEV cleavage site | Kan | 65 |
| pETFPP_2 | Expression vector; His6-MBP-3c cleavage site | Kan | 66 |
| pBAD-HisA | Expression vector, araBAD inducible promoter | Amp | Invitrogen |
| pCMF87 | pEHISTEV + ϕJoe int (gp53) | Kan | This study |
| pCMF90 | pGEM7 + S. coelicolor attRsc (274 bp) | Amp | This study |
| pCMF91 | pSP72 + ϕJoe attP (354 bp) | Amp | This study |
| pCMF92 | ϕJoe int + attP integrating vector; pSET152 | Apra | This study |
| pCMF94 | pGEM7 + S. coelicolor attLsc (419 bp) | Amp | This study |
| pCMF95 | pGEM7 + S. venezuelae attBsv (462 bp) | Amp | This study |
| pCMF96 | pETFPP_2 + ϕJoe MBP-RDF (gp52) | Kan | This study |
| pCMF97 | pGEM7 + S. coelicolor reconstituted attBsc (152 bp) | Amp | This study |
| pCMF98 | ϕJoe attLsv-attRsv; pCMF91 integrated into pCMF95 | Amp | This study |
| pCMF100 | pEHISTEV + ϕJoe RDF | Kan | This study |
| pCMF103 | pACYC184 + ϕJoe attLsv-lacZα-attRsv | Cm | This study |
| pCMF107 | pBAD + ϕJoe int | Amp | This study |
| pCMF108 | pBAD + ϕJoe RDF + int coexpression | Amp | This study |
| pCMF116 | pACYC184 + ϕJoe attBsv-lacZα-attP | Cm | This study |
| pCMF117 | pEHISTEV + ϕJoe RDF + int coexpression | Kan | This study |
| pGEM7 | General cloning vector | Amp | Promega |
| pSP72 | General cloning vector; accession no. X65332 | Amp | Promega |
| pACYC184 | General cloning vector; accession no. X06403 | Cm | 67 |
| pUZ8002 | Conjugation helper plasmid; RK2 derivative with defective oriT | Kan | 68 |
a
Apra, apramycin; Kan, kanamycin; Amp, ampicillin; Cm, chloramphenicol.